Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Anyang
Clinical trial register · South Korea

Clinical Trials in Anyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Anyang

25 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
AstraZeneca
Phase 3
2,800
Anyang, Cheonan-si, Seoul, Wŏnju, Yangsan
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,500
Anyang, Bucheon-si, Daegu, Seoul, Yangsan
2026-08-19
Not yet open
Seoul National University Hospital
Not applicable
1,724
Ansan, Anyang, Busan, Changwon, Cheonan, Daegu, Gwangju, Incheon
2026-07-29
Recruiting
The DECISION-CTO Extended 10 Y Follow-up
NCT06908499Coronary Artery Disease
Seung-Jung Park
Observational
840
Anyang, Bucheon-si, Busan, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2026-04-01
Recruiting
Jung-min Ahn
Phase 4
5,000
Anyang, Bucheon-si, Busan, Changwon, Cheonju, Chuncheon, Daegu, Daejeon
2025-07-24
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Anyang, Chungju, Daegu, Dong-gu Ulsan, Incheon, Seoul, Wŏnju
2025-06-09
Recruiting
Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
NCT06649240Ischemic Stroke, Small Vessel Cerebrovascular Disease, Cholesterol, LDL, Secondary Prevention
Seoul National University Hospital
Not applicable
4,016
Ansan, Anyang, Busan, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon
2024-10-04
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Anyang, Cheonan, Daegu, Daejeon, Gangwon-do, Goyang-si, Seongnam-si, Seoul
2024-08-30
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
Anyang, Busan, Seongnam-si, Seoul, Soeul, Suwon
2024-07-02
Recruiting
Seung-Jung Park
Not applicable
960
Seoul, Ansan, Anyang, Bucheon-si, Busan, Changwon, Chuncheon, Daegu
2024-04-25
Recruiting
CMG Pharmaceutical Co. Ltd
Phase 3
240
Anyang, Buchon, Busan, Cheonan, Daegu, Daejeon, Goyang-si, Guri-si
2024-04-19
Active, closed
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
NCT05995600Antiphospholipid Syndrome, Ischemic Stroke, Transient Ischemic Attack, Cerebrovascular Disease
Seoul National University Hospital
Phase 4
200
Anyang, Busan, Cheongju-si, Chuncheon, Daegu, Daejeon, Guri-si, Gwangju
2024-02-20
Recruiting
CrystalGenomics, Inc.
Phase 2
60
Anam, Anyang, Hwasun, Seoul, Yangsan
2023-08-23
Recruiting
Seung-Whan Lee, M.D., Ph.D.
Not applicable
2,400
Anyang, Bucheon-si, Busan, Changwon, Cheongju-si, Daegu, Gangneung, Iksan
2023-03-13
Recruiting
Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent
NCT05044273Coronary Artery Disease, Cardiovascular Diseases, Heart Diseases, Myocardial Ischemia
Jung-min Ahn
Observational
2,000
Anyang, Busan, Changwon, Daegu, Gangneung, Gwangju, Iksan, Seongnam
2022-09-01
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Busan, Daegu, Gwangju, Seoul, Anyang, Hwaseong-si, Seongnam
2022-04-05
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Busan, Daegu, Gwangju, Goyang-si, Anyang, Hwasŏng, Seongnam, Seoul
2022-03-15
Recruiting
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
NCT04416581Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
Duk-Woo Park, MD
Phase 4
3,320
Anyang, Bucheon-si, Busan, Changwon, Cheonan, Cheonju, Chuncheon, Daegu
2021-05-12
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Anyang, Daejeon, Gyeonggi-do, Jeju City, Seongnam-si, Seoul
2020-12-11
Recruiting
Seung-Whan Lee, M.D., Ph.D.
Observational
4,000
Anyang, Bucheon-si, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon, Gangneung
2018-01-11
Active, closed
IRIS-Onyx Cohort in the IRIS-DES Registry
NCT02593994Coronary Artery Disease, Arterial Occlusive Diseases, Cardiovascular Diseases, Percutaneous Transluminal Angioplasty
Seung-Jung Park
Observational
4,500
Seoul, Anyang, Bucheon-si, Cheonan, Chuncheon, Daegu, Daejeon, Gangneung
2015-10
Recruiting
Young-Hak Kim, MD, PhD
Not applicable
1,000
Seoul, Anyang, Chuncheon, Daegu, Pusan
2014-08-12
Recruiting
Seung-Jung Park
Observational
20,000
Anyang, Bucheon-si, Cheongju-si, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2011-06
Recruiting
Observational Study for Left Main Disease Treatment
NCT01341327Coronary Artery Disease
Seung-Jung Park
Observational
10,000
Anyang, Bucheon-si, Busan, Cheonan, Cheongju-si, Daegu, Daejeon, Gangneung
2007-07
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/anyang

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Anyang.

How many clinical trials are recruiting in Anyang?

18 of the 25 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Anyang), 25 studies
PhaseStudiesRecruitingShare
Phase 37428%
Observational6524%
Not applicable5420%
Phase 43212%
Phase 2228%
Phase 1114%
Phase 2/3104%

Most active sponsors

Lead sponsors with the most studies (Anyang)
Lead sponsorStudiesRecruiting
Seung-Jung Park54
Seoul National University Hospital31
AstraZeneca22
Jung-min Ahn22
Otsuka Pharmaceutical Development & Commercialization, Inc.20
Seung-Whan Lee, M.D., Ph.D.22
Alpine Immune Sciences Inc, A Subsidiary of Vertex10
Boehringer Ingelheim11
CMG Pharmaceutical Co. Ltd11
CrystalGenomics, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.